Parental and other factors associated with hydroxyurea use for pediatric sickle cell disease
Oyeku SO, Driscoll MC, Cohen HW, Trachtman R, Pashankar F, Mullen C, Giardina PJ, Velazco N, Racine AD, Green NS. Parental and other factors associated with hydroxyurea use for pediatric sickle cell disease. Pediatric Blood & Cancer 2012, 60: 653-658. PMID: 23129068, PMCID: PMC3625668, DOI: 10.1002/pbc.24381.Peer-Reviewed Original ResearchConceptsSickle cell diseaseHU useCell diseaseHematology providersBivariate analysisPediatric sickle cell diseaseBenefits of hydroxyureaMajor therapeutic effectMultivariate logistic regressionLong-term safetyPotential side effectsParental knowledgeBetter parental knowledgeHU usersHydroxyurea useInter-institutional variabilityParents of childrenChildren ages 5Label useSickle genotypeTherapeutic effectClinical careEffective treatmentSide effectsClinical practice